Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Progress in Nonmetastatic Prostate Cancer.

Smith MR.

N Engl J Med. 2018 Jun 28;378(26):2531-2532. doi: 10.1056/NEJMe1805733. No abstract available.

PMID:
29949488
2.
3.

Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer.

Kuo KF, Hunter-Merrill R, Gulati R, Hall SP, Gambol TE, Higano CS, Yu EY.

Clin Genitourin Cancer. 2015 Feb;13(1):10-6. doi: 10.1016/j.clgc.2014.08.003. Epub 2014 Aug 10.

4.

Hormonal Treatment for Nonmetastatic Disease Recurrence After Curative Treatment of Prostate Cancer: Only for a Select Few.

Tilki D, Evans CP.

Eur Urol. 2016 May;69(5):821-2. doi: 10.1016/j.eururo.2015.12.008. Epub 2015 Dec 21. No abstract available.

PMID:
26719013
5.

Summary of the Standards, Options and Recommendations for the management of patients with nonmetastatic prostate cancer (2001).

Villers A, Pommier P, Bataillard A, Fervers B, Bachaud JM, Berger N, Bertrand AF, Bouvier R, Brune D, Daver A, Fontaine E, Haillot O, Lagrange JL, Molinie V, Muratet JP, Pabot du Chatelard P, Peneau M, Prapotnich D, Ravery V, Richaud P, Rossi D, Soulie M; FNCLCC; AFU.

Br J Cancer. 2003 Aug;89 Suppl 1:S50-8. No abstract available.

6.

An evaluation of prostate specific antigen in prostatic cancer.

Guinan P, Bhatti R, Ray P.

J Urol. 1987 Apr;137(4):686-9.

PMID:
2435927
7.

Prostate-specific antigen--a true progress in diagnosis and follow-up of prostate cancer.

Allhoff EP, Olsson CA.

World J Urol. 1993;11(4):187. No abstract available.

PMID:
7508780
8.

High risk biochemical relapse and the timing of androgen deprivation therapy.

Ryan CJ, Small EJ.

J Urol. 2006 Dec;176(6 Pt 2):S61-5. Review.

PMID:
17084171
9.

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.

Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS.

J Clin Oncol. 2005 May 1;23(13):2918-25.

PMID:
15860850
10.

Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.

Yu EY, Miller K, Nelson J, Gleave M, Fizazi K, Moul JW, Nathan FE, Higano CS.

J Urol. 2012 Jul;188(1):103-9. doi: 10.1016/j.juro.2012.03.008. Epub 2012 May 12.

11.

Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort.

Dickinson L, Arya M, Afzal N, Cathcart P, Charman SC, Cornaby A, Hindley RG, Lewi H, McCartan N, Moore CM, Nathan S, Ogden C, Persad R, van der Meulen J, Weir S, Emberton M, Ahmed HU.

Eur Urol. 2016 Oct;70(4):668-674. doi: 10.1016/j.eururo.2016.02.054. Epub 2016 Mar 4.

PMID:
26951947
12.

Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer.

D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH.

J Urol. 2005 May;173(5):1572-6.

PMID:
15821488
13.

Re: Medium-Term Outcomes after Whole-Gland High-Intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort.

Taneja SS.

J Urol. 2016 Jul;196(1):103-4. doi: 10.1016/j.juro.2016.04.041. Epub 2016 Apr 14. No abstract available.

PMID:
27321502
14.

Survival and PSA-markers for mortality and metastasis in nonmetastatic prostate cancer treated with androgen deprivation therapy.

Nguyen-Nielsen M, Liede A, Maegbaek ML, Borre M, Harving N, Hernandez RK, Toft Sørensen H, Ehrenstein V.

Cancer Epidemiol. 2015 Aug;39(4):623-32. doi: 10.1016/j.canep.2015.05.008. Epub 2015 Jun 19.

PMID:
26100365
15.

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O'Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR; STAMPEDE Investigators.

N Engl J Med. 2017 Jul 27;377(4):338-351. doi: 10.1056/NEJMoa1702900. Epub 2017 Jun 3.

16.

Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.

Lodde M, Lacombe L, Fradet Y.

Urology. 2010 Nov;76(5):1189-93. doi: 10.1016/j.urology.2009.12.057. Epub 2010 Mar 29.

PMID:
20303155
17.

[Reliability and use of prostate-specific antigen in the management of patients with prostatic cancer].

Hübler J, Jávor A.

Orv Hetil. 1993 Jul 11;134(28):1529-32. Hungarian.

PMID:
7688112
18.

Rising PSA in nonmetastatic prostate cancer.

Moul JW, Bañez LL, Freedland SJ.

Oncology (Williston Park). 2007 Nov;21(12):1436-45; discussion 1449, 1452, 1454. Review.

19.

Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.

Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C.

J Clin Oncol. 2013 Oct 20;31(30):3800-6. doi: 10.1200/JCO.2012.44.6716. Epub 2013 Sep 16.

20.

Prostate-specific antigen and prostate cancer.

Rosalki SB, Rutherford FJ.

Int J Clin Pract. 2000 Nov;54(9):611-3.

PMID:
11220990

Supplemental Content

Support Center